Kineta Inc. filings document the corporate transition of a clinical-stage oncology biotechnology issuer whose common stock was formerly registered under the Exchange Act. The record includes material-event reporting on stockholder voting for merger-related proposals and proxy disclosures tied to the company's capital structure, governance and transaction approvals.
The Form 15 filed by Kineta, LLC, as successor by merger to Kineta, Inc., records the termination of registration or suspension of reporting duties for Kineta common stock following the June 30, 2025 mergers that left Kineta, LLC as a wholly owned subsidiary of TuHURA Biosciences. Other disclosure categories include material agreements, proxy materials, shareholder voting matters, governance, capital-structure and registration-status disclosures.
Kineta (KA) filed a Form 4 disclosing that director Shawn Iadonato exercised 237,500 stock options on 06/23/2025 at strike prices of $0.36 and $0.611, actions triggered by full vesting upon shareholder approval of the TuHURA Biosciences merger.
To cover taxes, 52,353 shares were sold at $0.26 (Code F). Net of the sale, his direct holdings rose to 860,377 shares; combined with 8,553 shares held via an IRA, total beneficial ownership is 868,930 shares, a ~27% increase.
The transactions were contractual (Code M) rather than open-market purchases, signalling alignment but offering limited insight into insider sentiment.